Neurological disease biologics represent the most challenging and potentially most rewarding frontier in biotechnology. Biogen's LEQEMBI (lecanemab) — approved for early Alzheimer's disease in 2023 — is the first disease-modifying therapy for Alzheimer's, generating nearly $1 billion in global in-market sales in 2025 and establishing a commercial beachhead in a disease affecting 55 million people globally. Biogen's multiple sclerosis franchise — despite revenue pressure from generic competition — remains one of the largest MS portfolios in the industry. Takeda's rare neurological disease programs and Alnylam's RNAi therapies for hereditary transthyretin amyloidosis represent the other primary neurological disease platforms among the ten companies.
Topics Covered
• Alzheimer's Disease Treatment Landscape
• LEQEMBI Commercial Progress
• Multiple Sclerosis Market Dynamics
• Rare Neurological Disease
• Alnylam ATTR Amyloidosis
• Takeda Neurology Portfolio
• Pipeline Assessment
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. Alzheimer's Disease Treatment Landscape
4. LEQEMBI Commercial Progress
5. Multiple Sclerosis Market Dynamics
6. Rare Neurological Disease
7. Alnylam ATTR Amyloidosis
8. Takeda Neurology Portfolio
9. Pipeline Assessment
10. Competitive Landscape
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
